86 related articles for article (PubMed ID: 15931264)
21. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
22. Antileukemic activity of Flt3 ligand in murine leukemia.
Wang A; Braun SE; Sonpavde G; Cornetta K
Cancer Res; 2000 Apr; 60(7):1895-900. PubMed ID: 10766177
[TBL] [Abstract][Full Text] [Related]
23. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
Rosnet O; Bühring HJ; Marchetto S; Rappold I; Lavagna C; Sainty D; Arnoulet C; Chabannon C; Kanz L; Hannum C; Birnbaum D
Leukemia; 1996 Feb; 10(2):238-48. PubMed ID: 8637232
[TBL] [Abstract][Full Text] [Related]
24. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
[TBL] [Abstract][Full Text] [Related]
26. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao Q; Nishiuchi R; Kitamura T; Kersey JH
Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
[TBL] [Abstract][Full Text] [Related]
27. Normal and oncogenic FLT3.
Naoe T; Kiyoi H
Cell Mol Life Sci; 2004 Dec; 61(23):2932-8. PubMed ID: 15583855
[TBL] [Abstract][Full Text] [Related]
28. The role of FLT3 in haematopoietic malignancies.
Stirewalt DL; Radich JP
Nat Rev Cancer; 2003 Sep; 3(9):650-65. PubMed ID: 12951584
[TBL] [Abstract][Full Text] [Related]
29. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
[TBL] [Abstract][Full Text] [Related]
30. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.
Hofmann M; Große-Hovest L; Nübling T; Pyż E; Bamberg ML; Aulwurm S; Bühring HJ; Schwartz K; Haen SP; Schilbach K; Rammensee HG; Salih HR; Jung G
Leukemia; 2012 Jun; 26(6):1228-37. PubMed ID: 22289926
[TBL] [Abstract][Full Text] [Related]
31. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
Bruserud Ø; Hovland R; Wergeland L; Huang TS; Gjertsen BT
Haematologica; 2003 Apr; 88(4):416-28. PubMed ID: 12681969
[TBL] [Abstract][Full Text] [Related]
32. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
33. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
34. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
35. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines.
Oveland E; Wergeland L; Hovland R; Lorens JB; Gjertsen BT; Fladmark KE
Cell Biol Toxicol; 2012 Aug; 28(4):201-12. PubMed ID: 22422053
[TBL] [Abstract][Full Text] [Related]
36. Effects of Flt3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells.
Eder M; Hemmati P; Kalina U; Ottman OG; Hoelzer D; Lyman SD; Ganser A
Exp Hematol; 1996 Feb; 24(2):371-7. PubMed ID: 8641368
[TBL] [Abstract][Full Text] [Related]
37. Anti-human FLT3 monoclonal antibody that inhibits proliferation of monocytic leukemia cell line SHI-1.
Ju S; Xue Z; Ju S; Ge Y; Xie W; Zhu H; Pan J; Zhang X
Hybridoma (Larchmt); 2011 Feb; 30(1):61-7. PubMed ID: 21466287
[TBL] [Abstract][Full Text] [Related]
38. Isolation and characterization of a monoclonal antibody binding to the extracellular domain of the flk-2 tyrosine kinase receptor.
Rose C; Rockwell P; Yang JQ; Pytowski B; Goldstein NI
Hybridoma; 1995 Oct; 14(5):453-9. PubMed ID: 8575794
[TBL] [Abstract][Full Text] [Related]
39. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells.
Turner AM; Lin NL; Issarachai S; Lyman SD; Broudy VC
Blood; 1996 Nov; 88(9):3383-90. PubMed ID: 8896403
[TBL] [Abstract][Full Text] [Related]
40. FLT3 antibody-based therapeutics for leukemia therapy.
Li Y; Zhu Z
Int J Hematol; 2005 Aug; 82(2):108-14. PubMed ID: 16146840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
